ICMR teams up with Bharat Biotech Limited to develop coronavirus vaccine

The vaccine will be developed using the virus strain isolated at the ICMR's National Institute of Virology (NIV), Pune, a statement said.

delhi, coronavirus, coronavirus testing, covid testing, medics, doctors
Medics prepare to collect samples for swab tests from a COVID-19 mobile testing van, during the nationwide lockdown to curb the spread of coronavirus, at Ramakrishna Mission area in New Delhi.
Press Trust of India
1 min read Last Updated : May 09 2020 | 11:03 PM IST

Indian Council of Medical Research (ICMR) has partnered with Bharat Biotech International Limited (BBIL) to develop a fully indigenous vaccine for COVID-19, the apex health research body said on Saturday.

The vaccine will be developed using the virus strain isolated at the ICMR's National Institute of Virology (NIV), Pune, a statement said.

The strain has been successfully transferred from NIV to BBIL, it added.

"Work on vaccine development has been initiated between the two partners. The ICMR-NIV will provide continuous support to BBIL for vaccine development. ICMR and BBIL will seek fast-track approvals to expedite vaccine development, subsequent animal studies and clinical evaluation of the candidate vaccine," the health research body said in the statement.
 

The death toll due to COVID-19 rose to 1,981 and the number of cases climbed to 59,662 in the country on Saturday, according to the Union Health Ministry.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusLockdownhealthcareHealth crisisBharat Biotech

Next Story